Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
about
Pharmacological treatments for non-alcohol related fatty liver disease (NAFLD): a network meta-analysisA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDNon-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayBile acids are nutrient signaling hormonesBile acid metabolism and signalingNon-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decadesBile acid signaling in metabolic disease and drug therapyFarnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivoFarnesoid X Receptor an Emerging Target to Combat Obesity.miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in miceMetabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver CirrhosisProtective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signalObeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.Review article: the management of paediatric nonalcoholic fatty liver disease.Pathobiology of liver fibrosis: a translational success storyRecent advances in the development of farnesoid X receptor agonistsFocus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Current research on the treatment of primary sclerosing cholangitis.Bile Acid Metabolome after an Oral Lipid Tolerance Test by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver diseaseFXR and liver carcinogenesisFarnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in RatsRegulation of human class I alcohol dehydrogenases by bile acids.Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trialBile acid receptors in non-alcoholic fatty liver disease.Cysteine sulfinic acid decarboxylase regulation: A role for farnesoid X receptor and small heterodimer partner in murine hepatic taurine metabolism.Emerging drugs for non-alcoholic steatohepatitis.Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.Bile acid receptors as targets for drug development.Pharmacological agents for NASH.Evolving therapies for non-alcoholic steatohepatitis.Diagnosis and management of primary biliary cirrhosis.Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion.Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?Pharmacotherapy for Nonalcoholic Fatty Liver Disease.Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.Novel Pharmacotherapy Options for NASH.
P2860
Q24186865-17323E66-96C3-468C-AD52-05DB8CE884D7Q26752487-9E86318B-C862-46CA-9409-45A1EFEFFAFFQ26800894-AAB1B929-D6E1-472A-A002-53D6EA8B75B6Q26822467-247EF183-62ED-4F26-BE19-DF1DEF1F177EQ27002873-1B095B1C-D780-48A3-B4EE-47DD996EC625Q27006992-82B5DE30-42BA-4EA6-8C4F-9D88917CA4F7Q28240299-7B530009-5901-4A60-B15F-6FA9F79DDC75Q28244875-7D5772C9-7072-42B8-965C-E4EE57D8B21DQ28296042-C720C54B-9D03-4918-9F27-331EBB61D61DQ30235507-1C6DDC7F-230A-4453-9BAB-391AEAE2AB9FQ33815927-FB7AFA1F-1E9C-45CC-BC2E-C504F732AFBFQ33891552-4838ABB0-24A7-4100-A170-71A9A831A938Q34098522-E891B0B7-0807-4DB7-8B1C-1A46A2C7D161Q34386625-EEDCB0CD-F7C4-4FAD-A16C-43534E90F9DBQ34440962-1F1B9886-7896-4AA8-B56B-16C8FCF4A0D5Q34462733-033A7F9D-EEC0-41BF-AA44-CABE77024EBFQ34464043-6B5ECBCC-D378-4F79-B1E2-A0FF44431E3FQ34647400-47A3535D-7B05-4005-B5BA-8555C4A82633Q35066561-3EEFBB73-F963-466C-94EB-4F92907C52A7Q35919570-628552F9-C6C0-4A88-803E-B2BF020CBEB9Q35933350-436AD04D-2D9D-499E-A482-EFF788CD5D96Q36052383-291824F1-FCA2-4181-9ADE-FB934ACEDFFBQ36063712-3DE7DD29-39EF-466F-A7D4-C0155BFA6316Q36242886-6CDF1070-74E0-43AA-B44B-4C3B2EE232C7Q37076509-B42FCC3C-3D24-4FE8-8C80-AA2E5F485F2CQ37515585-7B0CD608-02AB-4F16-BBF3-7A6C842B207BQ37586952-6D88B46A-E749-4E11-B926-13C968C42A96Q37717008-00BAE037-9479-4C58-8534-060DFA18BEF4Q38121137-7C18A601-1293-478C-8664-069879A21265Q38121574-A3EB1598-414A-42BB-843D-B43EC1D9E2E6Q38132058-56924E65-14E3-463C-A61F-11E3B7CA305BQ38152646-7D41A64F-D210-4B55-9DB1-6E723FEBC657Q38207111-FCDB0F7A-D29E-4436-918B-32AE7F8B33D4Q38266358-E25BDD16-7391-4051-A328-D4C16973F4A3Q38307168-B98A46E0-3C4F-49FB-930E-C3F6059C715AQ38397177-5DA5E011-80D6-44C1-AC9E-916920A07B76Q38516786-EDBDB2BF-BE9A-4E08-94B3-6B31FAEA5B71Q38588344-26F7AB6F-6742-493B-AD5F-2F19281F405CQ38597033-2BB5BCDD-EE95-4D69-ACB5-256C3F5E8ED0Q38784790-8535CBAC-7C33-48D5-867E-EDC0D0CF74DC
P2860
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@ast
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@en
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@nl
type
label
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@ast
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@en
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@nl
prefLabel
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@ast
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@en
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@nl
P2093
P1433
P1476
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
@en
P2093
David Shapiro
Luciano Adorini
Mark Pruzanski
P304
P356
10.1016/J.DRUDIS.2012.05.012
P577
2012-05-29T00:00:00Z